Tony Berberabe, MPH

Articles

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC

December 12th 2025

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

Trastuzumab Deruxtecan Plus Pertuzumab Does Not Worsen QOL in HER2+ Metastatic Breast Cancer

December 10th 2025

Frontline treatment with T-DXd plus pertuzumab improved QOL vs THP in patients with HER2-positive advanced or metastatic breast cancer.

Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL

December 9th 2025

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

Linvoseltamab Generates Responses in Newly Diagnosed Myeloma

December 8th 2025

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

CAMMA 3 Data Support Ongoing Investigation of Cevostamab in Heavily Pretreated Myeloma

December 8th 2025

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Axatilimab Dosing Shift Shows Feasibility in cGVHD

December 6th 2025

The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

December 6th 2025

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC

October 19th 2025

Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels

June 2nd 2025

The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.

MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC

May 31st 2025

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

April 29th 2025

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

December 12th 2024

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer

December 11th 2024

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

December 10th 2024

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma

October 1st 2024

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

September 27th 2024

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

September 18th 2024

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.